The landscape for myasthenia gravis, including generalized and ocular myasthenia gravis, is rapidly evolving. We have a number of different treatment strategies that have been recently approved. Those that are targeting B cells or the factories of autoantibody production, mainly inebilizumab as one of those. But there are a number of different clinical trials that are currently underway, and some nearing completion, with some with already having preliminary data that are looking at cell therapies or CAR-T therapies, demonstrating favorable responses...
The landscape for myasthenia gravis, including generalized and ocular myasthenia gravis, is rapidly evolving. We have a number of different treatment strategies that have been recently approved. Those that are targeting B cells or the factories of autoantibody production, mainly inebilizumab as one of those. But there are a number of different clinical trials that are currently underway, and some nearing completion, with some with already having preliminary data that are looking at cell therapies or CAR-T therapies, demonstrating favorable responses. These are not yet approved for use in patients with generalized myasthenia gravis, but certainly near on the horizon. We have a number of different other strategies that are targeting B cells or B cell development that are very encouraging. Telitacicept, which was approved in China for the treatment of generalized myasthenia gravis, is currently being studied in a Phase III international or global clinical trial, with results likely soon to be announced. These are not just available as yet, but that’s encouraging. So I think we’ll have a number of different modalities to target patients with myasthenia gravis, not only downstream but upstream mechanisms that are driving disease. Over the last decade or so, we certainly have a number of downstream targeting strategies, such as FcRn antagonists and complement inhibitors, with multiple medications in both of those classes that are currently approved both in Europe and also in the US. But a number of other strategies in those groups are currently under investigation that might result in either a lesser burden of treatment for patients or even better outcomes overall. So the landscape is very encouraging, very promising from that perspective. Many patients with myasthenia gravis do continue to have inadequate disease control. So while it’s encouraging to have new therapies available, not every single patient will respond to every single therapy available out there. So having multiple medication strategy options available for our patients is extremely important. Not one shoe size fits all is kind of how I look at it. So having the availability of multiple strategies is very encouraging. How we utilize those strategies is still a current knowledge gap: when to use which medication option for which patient, and at what point in their disease. These are unanswered questions. I think there’s still quite a bit of work to do, still quite a bit of research in the area of application of biologics or targeted therapy strategies for our patients. Having validated predictive markers of outcome, or markers that can predict which patients will be responsive or not responsive, for instance, to certain therapies, is certainly critically important as the next step in improving the care of patients with autoimmune myasthenia gravis at this time.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
